1. Home
  2. MEVOU vs XOMAP Comparison

MEVOU vs XOMAP Comparison

Compare MEVOU & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MEVOU

M Evo Global Acquisition Corp II Units

N/A

Current Price

$10.01

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Logo XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMAP

XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

N/A

Current Price

$26.48

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MEVOU
XOMAP
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
14
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MEVOU
XOMAP
Price
$10.01
$26.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.7K
1.3K
Earning Date
N/A
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.01
$24.96
52 Week High
$10.50
$27.30

Technical Indicators

Market Signals
Indicator
MEVOU
XOMAP
Relative Strength Index (RSI) 43.49 58.59
Support Level N/A $26.05
Resistance Level $10.05 $26.87
Average True Range (ATR) 0.02 0.21
MACD -0.00 0.12
Stochastic Oscillator 0.00 52.80

Price Performance

Historical Comparison
MEVOU
XOMAP

About MEVOU M Evo Global Acquisition Corp II Units

M Evo Global Acquisition Corp II is a blank check special purposr acquisition company.

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.

Share on Social Networks: